Teriparatide

Generic Name: Teriparatide

Brand Names: Forsteo, Forteo, Movymia, Kauliv, Sondelbay, Teriparatide Sun, Terrosa, Livogiva

Drug Type: Biotech

Chemical Formula: -

CAS Number: 52232-67-4

Unique Ingredient Identifier: 10T9CSU89I

Background: Teriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Europe in April 2003, teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic th...

Indication: Teriparatide is indicated:

Associated Conditions: Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Primary Osteoporosis

Associated Therapies: -

Clinical Trials

MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

Phase 4

Completed

Conditions: Diabetes Type 2
Postmenopausal Osteoporosis

Interventions: Drug: Prolia, 60 Mg/mL Subcutaneous Solution
Drug: Teriparatide

First Posted Date: 2018-03-21

Last Posted Date: 2023-01-26

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 26

Registration Number: NCT03472846

Locations: 🇦🇹
Medical University Vienna; St. Vincent Hospital, Vienna, Austria

The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA

Phase 3

Conditions: Unstable Intertrochanteric Fracture

Interventions: Drug: Teriparatide
Drug: Placebo
Dietary Supplement: Calcium supplement
Dietary Supplement: Vitamin D

First Posted Date: 2017-04-28

Last Posted Date: 2020-09-09

Lead Sponsor: King Chulalongkorn Memorial Hospital

Target Recruit Count: 60

Registration Number: NCT03133195

Locations: 🇹🇭
Faculty of Medicine Chulalongkorn University, Bangkok, Thailand

Teriparatide as a Chondroregenerative Therapy in OA

Phase 2

Completed

Conditions: Knee Osteoarthritis
Cartilage Degeneration

Interventions: Drug: Placebo
Drug: Teriparatide

First Posted Date: 2017-03-07

Last Posted Date: 2023-05-12

Lead Sponsor: Christopher Ritchlin

Target Recruit Count: 76

Registration Number: NCT03072147

Locations: 🇺🇸
URMC Orthopaedics, Clinton Crossings Building D, Rochester, New York, United States

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

Phase 2

Completed

Conditions: Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment

Interventions: Drug: Teriparatide
Drug: Thiazide
Drug: Potassium sparing diuretic
Drug: Alfacalcidol

First Posted Date: 2016-07-07

Last Posted Date: 2021-06-28

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 16

Registration Number: NCT02824718

Locations: 🇫🇷
AP-HP Hopital Europeen Georges Pompidou, Paris, France

A Comparison Study of PF708 and Forteo in Healthy Subjects

Phase 1

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide

First Posted Date: 2016-01-15

Last Posted Date: 2016-08-04

Lead Sponsor: Pfenex, Inc

Target Recruit Count: 70

Registration Number: NCT02656810

Locations: 🇺🇸
Covance Clinical Research Unit, Evansville, Indiana, United States

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects

Phase 1

Completed

Conditions: Drug Safety and Bioavailability

Interventions: Drug: Teriparatide
Drug: Oral PTH (1-34)

First Posted Date: 2015-10-08

Last Posted Date: 2018-01-10

Lead Sponsor: Entera Bio Ltd.

Target Recruit Count: 30

Registration Number: NCT02571140

PTH and Vibration in OSteoporosis Study

Not Applicable

Completed

Conditions: Osteoporosis

Interventions: Other: whole-body vibration
Drug: teriparatide

First Posted Date: 2015-09-30

Last Posted Date: 2020-09-18

Lead Sponsor: Odense University Hospital

Target Recruit Count: 35

Registration Number: NCT02563353

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

Phase 1

Completed

Conditions: Postmenopausal Osteoporosis

Interventions: Drug: ZP-PTH
Drug: FORTEO

First Posted Date: 2015-06-23

Last Posted Date: 2016-08-23

Lead Sponsor: Zosano Pharma Corporation

Target Recruit Count: 24

Registration Number: NCT02478879

Locations: 🇺🇸
Covance Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States

Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication

Completed

Conditions: Osteoporosis, Postmenopausal
Osteoporosis, Steroid Induced

First Posted Date: 2015-06-16

Last Posted Date: 2019-01-10

Lead Sponsor: 251 Hellenic Air Force & VA General Hospital

Target Recruit Count: 851

Registration Number: NCT02472782

Locations: 🇬🇷
251 Hellenic Air Force & VA General Hospital, Athens, Attiki, Greece

Renal Osteodystrophy: An Individual Management Approach

Not Applicable

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: Alendronate
Drug: Teriparatide
Drug: Cinacalcet

First Posted Date: 2015-05-12

Last Posted Date: 2023-01-05

Lead Sponsor: Hartmut Malluche, MD

Target Recruit Count: 141

Registration Number: NCT02440581

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy